Although effective in the treatment of eosinophilic esophagitis (EoE) in children, limited data exist on long-term safety and effi cacy of swallowed topical corticosteroids. We investigated whether longterm use of swallowed fl uticasone in children with EoE leads to sustained reduction in esophageal eosinophils, and endoscopic and clinical improvement.
INTRODUCTION
Eosinophilic esophagitis (EoE) is a chronic immune-mediated infl ammatory disease of the esophagus ( 1, 2 ) . EoE is characterized clinically by symptoms of esophageal dysfunction including abdominal pain, regurgitation, vomiting, dysphagia, and esophageal food impactions ( 3, 4 ) . Many children with EoE fail to thrive unless treated successfully ( 4 ) . Esophageal features that can be identifi ed endoscopically and are indicative of clinical symptoms include fi xed esophageal rings (trachealization), strictures, longitudinal furrows, exudates (white plaques), and edema ( 5 ) . Th e histological hallmark of the disease is infi ltration of the esophagus by eosinophils (≥15 eosinophils/high power fi eld (HPF) in the maximally involved area ( 2 ) ). Per defi nition, both clinical and histopathological features are refractory to therapy with proton pump inhibitors (PPIs) ( 2 ) . EoE is associated with histological evidence of esophageal remodeling, even in young children ( 6 ) , and if left untreated can lead to esophageal dysmotility and strictures ( 7 ) .
Th e prevalence of EoE in children has been increasing, currently approaching that of pediatric Crohn's disease and ulcerative colitis (8) (9) (10) (11) . Goals of therapy currently include improvement of clinical symptoms, remission of histopathological features, and avoidance of long-term complications. However, no FDA-approved medical therapies for EoE exist to date ( 12 ) . Available therapeutic approaches include various dietary restrictions and off -label use of topical corticosteroids to the esophagus ( 2 ) . Given the chronic nature of EoE, its tendency to develop progressive fi brosis over time that is reversible with therapy in children ( 13 ) , and its tendency to relapse within a few weeks to months following discontinuation of therapy ( 14 ) , long-term therapy for EoE is needed. Although dietary restriction therapies can be used chronically in children with EoE (15) (16) (17) (18) (19) (20) , their long-term acceptance by patients has been a challenge ( 21 ) . Topical corticosteroids in the form of fl uticasone propionate (FP) to swallow ( 14, (22) (23) (24) (25) (26) (27) (28) or oral viscous budesonide (29) (30) (31) (32) have been shown to be eff ective in children, as demonstrated by several case series and short-term randomized controlled trials, but their effi cacy or safety for chronic use has not yet been established. Th e longest treatment duration reported is 6 months in children ( 28 ) , with some effi cacy of the drug still demonstrated and with minimal side eff ects. Whether this eff ect is sustained beyond 6 months is unknown.
Our objective was to investigate the long-term effi cacy and safety of swallowed FP in children with EoE. We hypothesized that, in pediatric patients with EoE, maintenance therapy with swallowed FP leads to a sustained improvement of eosinophilic infi ltration of the esophagus, as well as endoscopic and clinical features. We also investigated the safety of long-term swallowed FP administration in children.
METHODS

Design and participants
We conducted an open-label, prospective, single-center study of long-term swallowed FP as a maintenance therapy for children with EoE. All pediatric patients (age 2-18 years) with confi rmed active EoE seen at the Mount Sinai Center for Eosinophilic Disorders between June 2006 and August 2012 were off ered FP. Th e choice of this therapy was made by participants and their families. Options off ered to everyone included an empiric elimination diet consisting of dietary removal of common EoE food triggers, an elemental diet consisting of exclusive feeding of an amino acid-based formula with one food, or FP to swallow. Each option was off ered for long-term use if proven eff ective clinically and histologically aft er short-term therapy ( Figure 1 ). All participants provided consent, and assent when applicable, to have all their data analyzed, following approval from the Institutional Review Board at our institution. Active EoE was defi ned as the presence of esophageal symptoms and histological evidence of ≥15 eosinophils/HPF in the maximally involved areas of the esophagus on esophagogastroduodenoscopy with biopsies despite prior therapy with a PPI per current consensus recommendations ( 1, 2 ) . Patients with evidence of concomitant eosinophilic gastritis and/or enteritis, active Helicobacter pylori infection, or parasitic infection were excluded.
For all subjects, baseline clinical, endoscopic, and histological assessments were obtained before therapy with fl uticasone.
Pharmacological treatment
Th erapy with FP metered dose inhaler was given as two puff s to swallow twice a day, specifi cally aft er breakfast and at bedtime. All patients were instructed to puff the medication into their mouth without synchronous deep inhalation or the use of a spacer. Th ey were also instructed not to eat, drink, rinse their mouth, or brush their teeth for an hour in the morning and then all night at bedtime aft er taking fl uticasone. Th e dose of swallowed FP was modeled according to age-specifi c treatment doses for asthma. Th ree diff erent strengths of FP were used according to age: 2-4-year old: 44 μ g/puff ; 5-11-year old: 110 μ g/puff ; and ≥12-year old: 220 μ g/ puff . Th e dose was unchanged over time, unless disease relapse without an identifi able cause was observed. Correct administration was demonstrated, and proper adherence was discussed by instructing the subjects and their families to check the reading on the counter that is fi tted to the back of the inhaler. At study entry, diets were liberalized for any patients who were on dietary restriction therapy for EoE.
Aft er short-term therapy with fl uticasone, patients were instructed to follow-up at our Center for repeat clinical, endoscopic,
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Fluticasone as Maintenance Therapy for Children With EoE and histological evaluations. If patients achieved disease remission with the above therapy, defi ned as complete resolution of their main symptom and histological clearance of esophageal eosinophils to <15/HPF in the maximally involved area on biopsies, swallowed FP was continued at the same dose with clinical follow-up assessments every 4 months and endoscopic and histological follow-up assessments yearly. Additional unscheduled clinical, endoscopic, and histological evaluations were carried out in the event of re-emergence of esophageal symptoms at any time during their therapy. Clinical data that were collected at the time of endoscopic assessments were included in the analysis. Proper use of FP was demonstrated at every follow-up visit. Adherence to FP was also monitored at every follow-up visit by reminding the subjects and their families to check the reading on the counter that is fi tted to the back of the inhaler and, when needed, by calling the dispensing pharmacy to check on the number of refi lls obtained. Potential side eff ects were investigated at every follow-up visit.
Although a systematic follow-up schedule was designed for the study as described above, some patients followed individualized schedules based on personal schedules and dictated by symptoms and disease activity. Patients had clinical, endoscopic, and histologic data available at all reported time points.
Study end points
Th e primary end point of the study was reduction over time in the peak esophageal eosinophil count in the maximally involved area of the esophagus, achieved with swallowed FP. We also reported reduction in peak eosinophil count in the distal and proximal esophagus, respectively. Secondary end points were as follows: (1) determination of histological remission over time, as measured by reduction in peak eosinophil counts to <15, <10, and <5 eosinophils/HPF (all three end points were considered as histological remission is currently not yet defi ned) ( 1, 12 ) ; (2) improvement of esophageal histologic features other than the intraepithelial eosinophil count; (3) resolution of esophageal remodeling as determined by the presence of sub-epithelial lamina propria fi brosis; (4) improvement of endoscopic features; and (5) improvement of clinical symptoms.
Histological evaluation
Hematoxylin and eosin-stained slides were blindly evaluated by two pathologists (M.G.H. and M.S.M.). All esophageal biopsies were scanned at ×100 power. Four distal esophageal, 4 proximal esophageal, 2 gastric antral, 2 gastric fundic, and 4-6 duodenal biopsies were obtained at each procedure for evaluation, in addition to any sites with macroscopically abnormal areas. From the area of maximum intraepithelial eosinophilic density, the number of intraepithelial eosinophils was then reported for the ×400 HPF (0.237 mm 2 ) with the highest concentration of eosinophils (peak count). Eosinophils were counted both when the entire cell including the nucleus was evident and/or when a discrete cluster of eosinophilic granules was identifi ed. Th e highest eosinophil count found in the distal and proximal esophageal biopsies was recorded for analysis. Th e following additional histological features were recorded ( 6 ): presence of eosinophilic microabscesses (defi ned as a cluster of ≥4 eosinophils), presence and extent of eosinophilic degranulation (graded under HPF as absent/mild= 0 to few extracellular granules; or extensive= moderate-to-marked degranulation), superfi cial layering of intraepithelial eosinophils, epithelial basal zone thickness in well-oriented sections (graded from 0 to 3 based on its proportion of the total epithelial thickness; 0=≤20% total epithelial layer thickness, 1=20% to 1/3 thickness, 2=1/3-2/3 thickness, 3=≥2/3 to full thickness), presence of dilated intercellular spaces, and the presence of lamina propria fi brosis. Edges of the biopsy specimen and areas with crush artifact were excluded from evaluation. Histological features were assessed over time.
Endoscopic evaluation
All pre-and post-treatment endoscopies were performed by the same gastroenterologist (M.C.) who recorded six macroscopic features (rings, white plaques, furrows, decreased vascular pattern (edema), stricture, and esophageal shearing). Th ese were then graded using the modifi ed classifi cation and grading system published by Hirano et al. for adults with EoE ( 5 ). A fi nal score was calculated for each patient at every endoscopy by summing up the grades given for every feature and dividing it by the number of features assessed (six features). Double weight was given to rings and strictures in the fi nal summation score, as their rare presence in the pediatric population indicates severe and advanced disease ( 6 ) . Median endoscopy scores were compared over time.
Clinical evaluation
Clinical evaluations included a history and physical exami nation with measurements of height and weight. Up to eight clinical symptoms (abdominal pain, nausea, vomiting, regurgitation, chest pain, dysphagia, food impaction, and early satiety) were assessed for their presence by parent and patient. A symptom score was calculated at each visit by dividing the number of clinical symptoms present per patient by the total number of symptoms assessed at that visit (up to 8 symptoms). Median clinical scores were compared over time.
Peripheral eosinophil counts
Eosinophils in peripheral blood were measured on the same day of every endoscopy and reported as cells per μ l.
Safety
As candida infections and growth delay have been subjects of concern with topical corticosteroid use in children with EoE, side eff ects were monitored by clinical history, physical examination, and following of growth by calculating the z score for height and weight for all patients over time using the SAS program for the CDC 2000 growth charts (2 to ≤20 years) ( http://www.cdc.gov/nccdphp/ dnpao/growthcharts/resources/sas.htm ). Occurrence of oropharyngeal or esophageal candida infection was recorded and treated without interruption of FP maintenance therapy. As alteration of the hypothalamic pituitary adrenal (HPA) axis is a concern with longterm steroid use, morning serum cortisol levels were collected when prompted by parental anxiety regarding chronic use of steroids.
Statistical analysis
Intention-to-treat analysis was performed. Statistical analysis was performed by the use of the SAS statistical soft ware package, version 9.3. Follow-up time points were grouped by timing of endoscopies into <4 months, 4-12 months, 13-24 months, and >24 months intervals. Depending on individual initial treatment timing and follow-up schedules, participants had none, one, or multiple endoscopies per time period at the time of data analysis. Comparison for all outcomes was made from baseline (before treatment) to the four diff erent follow-up intervals on therapy. Statistical signifi cance between groups of data were determined by the use of the paired t -test for continuous variables. Secondary histological outcome evaluating diff erent cutoff s for remission (<15, <10, and <5 eosinophils/HPF) was calculated using McNemar's test for categorical variables. Th e correlation coeffi cient between the endoscopic score and individual histological features was calculated adjusting for intraclass correlation. Mean z -scores for height and weight at baseline of all patients were compared with all follow-up times using paired t -tests. For comparisons of continuous variables between patients who started FP as fi rst therapy and those switching from diet, the Mann-Whitney U test for non-parametric continuous data was used. Statistical signifi cance was determined at P <0.05.
Mixed linear regression model
We fi tted a mixed linear regression (negative binomial) model to test the hypothesis that treatment initiation would lead to a sustained decrease in the histological outcome, the peak eosinophil count, our response variable, while accounting for correlation of repeated observations in the same patient in a per patient analysis.
Very briefl y, in our models, we modeled the population averaged peak eosinophil count response with fi xed eff ects using the predictors treat (indicating treatment initiation) and further followup (indicating subsequent follow-up observations), controlling for the potential confounders Diet (prior diet modifi cation) and PPI (prior proton inhibitor treatment) and allowing for individual patient (random) intercepts and further follow-up (to account for the correlation between repeated measurement in the same patient and the variability in patient response). Over-dispersion led us to prefer a negative binomial over a poisson model. Th e most parsimonious model was selected based on the expected log predicted density, but inclusion of potential confounders and/or omission of the random eff ect to allow for individual patient long-term eff ects (further follow-up) did not aff ect the inferences.
We fi tted our mixed models in the statistical soft ware environment R ( 33 ) . We used the R package rstanarm ( 34 ) as an interface to the Stan statistical programming language ( 35 ) to implement our model with Stan's Hamiltonian Monte Carlo algorithms. We used the R package shinystan ( 36 ) to explore the Monte Carlo Markov Chain output, render some graphs, and confi rm model convergence. We relied on Rhat as a convergence diagnostic ( 37 ) . Additional details on model formulation and building is included in the Supplementary Material (Supplementary statistical modeling information).
RESULTS
Participants
Fift y-four patients with a diagnosis of active EoE chose FP to swallow as treatment option and were enrolled in the study. Patients were predominantly male (80%) with a median age of 6.5 years (range 2-17 years). Th e majority of patients (85%) had other atopic conditions such as asthma (57%), allergic rhinitis (68%), and/or atopic dermatitis (31%). Seventy-four percent had a history of immunoglobulin E (IgE)-mediated food allergy ( Table 1 ). As patients with EoE oft en have an atopic background, including IgE-mediated food allergy, atopic dermatitis, allergic rhinitis, and asthma, the question remains whether EoE disease severity and progression is infl uenced by an atopic predisposition ( 15, 16, 25, 38 ) . Th e primary outcome (peak eosinophil count) was compared for these atopic conditions. An underlying diagnosis of an atopic disease in a patient (asthma, allergic rhinitis, atopic dermatitis, and food allergy) did not correlate with severity of EoE measured as peak esophageal eosinophil count ( P values >0.4 for all atopic features examined). Only three patients continued PPI therapy throughout their treatment with swallowed FP.
FP was the fi rst treatment modality chosen by 15 patients; an additional 39 children had been on dietary restriction therapy before opting for swallowed FP, and their diets were fully liberalized at study entry. All but two patients who had been on a diet before changing to FP had failed dietary restriction therapy. Baseline characteristics were comparable for those two subgroups ( Table 2 ) .
Of the 54 participants, 2 were lost to follow-up and 8 withdrew from therapy with swallowed FP, 7 due to lack of histological PEDIATRICS Fluticasone as Maintenance Therapy for Children With EoE understand treatment response and histologic remission, resolution of eosinophilic infi ltration was evaluated applying three different criteria (<15 eosinophils/HPF, <10 eosinophils/HPF, and <5 eosinophils/HPF).
Th e percentage of patients who achieved remission when analyzed at the various intervals (<4 months, 4-12 months, 13-24 months and >24 months) were as follows <15 eosinophils/HPF in the most severely aff ected area: 83%, 84%, 59%, 63%; <10 eosinophils/HPF in the most severely aff ected area: 75%, 78%, 51%, 58%; and <5 eosinophils/HPF in the most severely aff ected area: 63%, 66%, 48%, 58% ( Supplementary Table 1 ) .
When distal and proximal esophageal peak eosinophil counts were analyzed separately, similar results were seen with respect to the remission rate: Distal esophagus (<4 months, 4-12 months, 13-24 months and >24 months): <15 eosinophils/HPF-83%, 88%, 63%, 63%; <10 eosinophils/HPF-75%, 84%, 56%, 58%; <5 eosinophils/HPF-63%, 69%, 48%, 58%. Proximal esophagus (<4 months, 4-12 months, 13-24 months and >24 months): <15 eosinophils/HPF-88%, 84%, 81%, 79%; <10 eosinophils/HPF-88%, 81%, 81%, 79%; <5 eosinophils/HPF-88%, 72%, 81%, 74%.
Of the 43 patients who achieved remission at the fi rst follow-up endoscopy, a total of 13 patients had relapse during their follow-up course, 6 of whom had multiple relapses, for a total of 25 relapse occurrences for all patients ( Supplementary Figure 1 ) . Eighteen of 25 relapse occurrences were noted to mainly aff ect the distal esophagus: median eosinophils/HPF 37 in the distal esophagus (range 15-182) and 2 in the proximal esophagus (range 0-99). Reasons for relapse in these patients were non-adherence to swallowed response at various time points during therapy, and 1 for parental concern over chronic steroid use. Forty-four patients remained on treatment at the time of data analysis. All 54 patients were included in the data analysis.
Mean duration of follow-up of patients aft er initiation of swallowed FP was 20.4 months (1.7 years), with the longest being 68 months (5.7 years).
Effi cacy
Peak esophageal eosinophil count (primary end point) . Treatment with swallowed FP signifi cantly decreased the maximum number of eosinophils/HPF in the most severely aff ected area of the esophagus at all follow-up time points compared with baseline (median 72 eosinophils/HPF at baseline compared with median 0.5 eosinophils/HPF at follow-up within 4 months; and 1.75 eosinophils/HPF, 10 eosinophils/HPF, and 12 eosinophils/HPF at 4-12 months, 13-24 months, and >24 months follow-ups, respectively, all P <0.0001; Figure 2a ). Separate analysis of peak eosinophils in the distal and proximal esophagus showed a comparable reduction in peak eosinophils at all time points, res pectively. In the distal esophagus, median 60 eosinophils/HPF at baseline was present, compared with median 0.5 eosinophils/HPF at followup within 4 months, P <0.0001, and 1.0 eosinophils/HPF, 8 eosinophils/HPF, and 12 eosinophils/HPF at 4-12 months, 13-24 months, and >24 months follow-ups, respectively (all P values between <0.0001 and 0.0002). As for the proximal esophagus, median 55.5 eosinophils/HPF at baseline was present, compared with median 0 eosinophils/HPF at follow-up within 4 months, P <0.0001, and 0 eosinophils/HPF, 0.5 eosinophils/HPF, and 0.5 eosinophils/HPF at 4-12 months, 13-24 months, and >24 months follow-ups, respectively (all P values between <0.0001 and 0.0004; Figure 2b , c ).
Other histologic fi ndings . Although the peak number of eosinophils/HPF to diagnose EoE is clearly defi ned at ≥15, no consensus on criteria for histologic remission exists to date ( 12 ) . To better Andreae et al.
FP therapy (four patients), incorrect technique when the children took over the responsibility for medication administration as they got older (3 patients), and unidentifi ed cause (6 patients, one of whom responded to an increase in the dose as he grew into the next dosing category, and another responded to addition of a PPI). When present, each individual histologic feature showed significant improvement compared with baseline ( Table 3a ) . Peak eosinophil count signifi cantly correlated with the presence of secondary histologic features (eosinophilic microabscesses, eosinophil superfi cial layering, dilated intercellular spaces, basal zone hyperplasia, eosinophilic degranulation, and lamina propria fi brosis). Lamina propria adequate for evaluation was present in 75% of biopsies. At baseline, fi brosis of the lamina propria was noted in 91.5% of patients. Th e percentage of patients with lamina propria fi brosis decreased to 41% and remained similarly low at all follow-up periods ( Table 3a ) .
Endoscopic fi ndings .
Th e majority of children had white plaques (58.3%), furrows (75.5%), and edema (67.4%) on endoscopy. White plaques and furrows rapidly and signifi cantly responded to treatment. Resolution of edema was less pronounced short term but showed a signifi cant reduction between 4 and 24 months of treatment. Shearing was present in 4.2% of patients at baseline and quickly resolved with therapy. Fixed rings were found in 10.2% of patients, resolved aft er 4-12 months of FP treatment and did not recur, except in one patient in his second year of treatment with FP in the absence of esophageal eosinophilia. Rings cleared again on subsequent follow-ups. A stricture was found in 1/54 (1.85%) of patients at baseline. Aft er 7 months of treatment with FP, the stricture resolved and did not recur.
Th e cumulative score of endoscopic features signifi cantly improved with swallowed FP at all time points ( Table 3b ). Furthermore, the endoscopic score signifi cantly correlated with esophageal eosinophil counts and other histological features (correlation coeffi cient for peak eosinophils <15/HPF: −0.60476, P <0.0001; eosinophilic microabscesses: 0.64566, P <0.0001; eosinophilic degranulation: 0.62673, P <0.0001; eosinophil superfi cial layering: 0.61638, P <0.0001; dilation of intercellular spaces: 0.63599, P <0.0001; basal zone hyperplasia: 0.68110, P <0.0001; lamina propria fi brosis: 0.51159, P <0.0001).
Clinical fi ndings .
At baseline, most patients (88.9%) had at least one of eight assessed symptoms (abdominal pain, nausea, vomiting, regurgitation, chest pain, dysphagia, food impaction, and early satiety). With swallowed FP treatment, patients experienced a signifi cant decrease in the symptom score at all follow-up periods up to 2 years ( Table 3c ).
Per patient analysis and modeling . In our linear mixed eff ects model, initiation of treatment with swallowed fl uticasone led to a statistically signifi cant and sustained decrease in peak eosinophil counts. We present the detailed regression results of the most parsimonious model in Supplementary Table 2 and explain the fi ndings with a representative patient with a starting peak eosinophil count of 80/HPF, treatment initiation may suppress the peak eosinophil count to 10 at the fi rst endoscopy appointment and stays in remission at further follow-up appointments.
Numerically, the regression coeffi cient for treatment (2.1) equals the diff erence of the log of a starting peak eosinophil count (80 for a representative patient), minus the log of the peak eosinophil count at the fi rst appointment (10 for typical patient): log(80)-log(10)=2.1 (regression coeffi cient for treatment). More formally stated, in our mixed eff ects negative binomial regression model, the diff erence in the logs of expected peak eosinophil counts is expected to change by the respective regression coeffi cient, given the other predictor variables in the model are held constant.
Our model specifi cally investigated the hypothesis of sustained eff ect by contrasting the fi rst follow-up vs. subsequent follow-up. Th e estimate of the posterior median the regression coeffi cient for further follow-up supports the hypothesis of sustained reduction in peak eosinophil count in our cohort. For our exem plary patient, the peak eosinophil count would remain below 15. Safety . Asymptomatic candidal esophageal infection was seen in three patients at 4-12, 13-24, and >24 months, respectively. Esophageal candidiasis resolved with fl uconazole therapy as confi rmed by repeat endoscopy with biopsies, while FP therapy was continued.
Comparison of mean baseline height z -scores with mean height z -scores recorded at the four follow-up time periods revealed no signifi cant deviation from the projected growth curves ( P values 0.1479, 0.9602, 0.2263, and 0.1703 at 4-12, 13-24, and >24 months, respectively). A similar result was seen for weight z -scores However, the model estimated wide credible intervals for sustained eff ect, together with signifi cant patient variability, this means that the eff ect of swallowed fl uticasone is not consistent for all patients. Inter-patient variability may best explain the inter-individual differences (as seen in Figure 3 ) in patient responses, as a mixed eff ects model allowing patient-specifi c trajectories fi t our data better than the simpler model with only fi xed eff ects. Our models showed that diet modifi cation and prior treatment with PPIs do not aff ect our inferences.
Peripheral eosinophil counts . Median peripheral eosinophil count was 400/μ l (range 100-1,500/μ l) at baseline. No signifi cant change in peripheral eosinophil counts was noted at any follow-up The features are also summarized in a score (median/range) for endoscopic and clinical data at baseline and follow-up intervals. * P <0.05, ** P <0.01.
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of patients while taking swallowed FP ( P =0.7685, 0.9270, 0.4708, 0.5670 at 4-12, 13-24, and >24 months, respectively; Figure 4 ). Data on morning serum cortisol measurements were collected on nine patients. Morning cortisol levels ranged from 5.1 to 23.6 μ l (median 10.1 μ l). Two patients were found to be at the lower and higher end of the normal range for their age. Th ese patients had no clinical fi ndings, had normal growth, and a complete endocrine work-up was negative.
DISCUSSION
Th is is an important clinical trial that demonstrates that swallowed FP leads to a sustained long-term remission of EoE in children, defi ned as a reduction in peak eosinophil counts in the most aff ected area of the esophagus. Th is long-term oral steroid treatment was well tolerated and safe. Th is is particularly encouraging considering that to date no satisfying alternative long-term treatment options other than signifi cant dietary modifi cations are available ( 1,2 ) .
In our prospective study of pediatric patients with EoE, swallowed FP led to sustained improvement of histopathological, endoscopic, and clinical markers of disease severity. Treatment response of all disease markers in all patients was most pronounced at the fi rst short-term follow-up (at <4 months) but was maintained at subsequent follow-up time points for several months, the longest being 68 months. In addition, using a linear mixed eff ects model, we found that initiation of treatment with swallowed fl uticasone led to a statistically signifi cant and sustained decrease in peak eosinophil counts. Using the model, our confi dence in the sustained eff ect of swallowed fl uticasone obviously diminishes for later follow-ups where we have less data. We have less data beyond the third followup, not because of attrition (we lost only 6 out of 54 patients) but because patients were enrolled consecutively and not all have had years of follow-up yet. An update with additional long-term results as these become available in our ongoing trial is planned.
Although other pediatric studies have shown short-term response to FP using comparable dose ranges (22) (23) (24) (25) (26) (27) , this study adds to the literature by showing that this short-term eff ect can be maintained safely in pediatric patients for at least 2 years. Our fi ndings concur with and surpass previous studies analyzing the effi cacy of topical corticosteroids in inducing remission and histopathological, endoscopic, and symptom improvement with shortterm treatment ( 22, 23, 25, 26, 39, 40 ) .
Various factors likely played into this favorable study outcome. Th roughout the study, correct administration was demonstrated at length, strategies to ensure and enhance adherence were reviewed and discussed at every follow-up visit by the treating physician (M.C.), containers were checked when necessary and pharmacies were called to verify refi lls, and treatment was supervised by the caregivers in most patients. In addition, the design of our study, allowing patient and parent choice of therapy (diet vs. swallowed FP) likely improved the outcomes, as families were sharing the responsibility in the treatment process.
Clinical symptoms were recorded and tracked throughout the study. However, symptom severity measures were not used, and symptom report was based on patient and parent re-collection. Th is limitation in our study highlights the need for a standardized and validated clinical symptom questionnaire designed for pediatric patients with EoE.
Although open-label design is always a limitation, the fact that the families chose the therapy modality was not refl ected in their characteristics. Atopy and food allergy were comparable between patients who started swallowed FP as fi rst treatment modality vs. those who were on dietary restriction therapy fi rst ( Table 2 ) . Any change or restriction in diet was regarded as dietary modifi cation in our study. Th e degree of modifi cation was highly variable in our patients and included elemental diet, empiric 6-food elimination diet, or test-directed elimination diets. Th ese dietary After treatment initiation with swallowed fl uticasone, the peak eosinophil count decreases and remains low, with a minimal increase into the second year (possibly due to either decreasing adherence or treatment effi cacy) and increasing uncertainty as fewer patients were followed beyond 2 years. HPF, high power fi eld. 
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because of non-adherence, poor technique, or outgrown doses. It is possible that this observation is due to less contact time distally in the esophagus with smaller doses, as topical corticosteroid therapies were demonstrated to exert their function locally in the esophagus ( 46 ) . Our results demonstrate the necessity for optimal treatment adherence and dosing. We also demonstrate that transition of medication administration from caregiver to child may aff ect effi cacy of the drug and should be addressed during visits.
Our study design did not plan for dose increases as children grew. To evaluate whether growth might lead to outgrowing of the dose and resulting relapses, we analyzed all relapse occurrences for all patients. We found that only one of the six patients with unidentifi ed reasons for relapse responded to an increase in the dose of FP. We can therefore conclude that the relatively lower FP dose resulting from growth and weight gain is enough to maintain remission in most patients if good adherence and technique are achieved.
As for the four patients with disease relapse over time without an identifi ed etiology, it is possible that they have developed resistance to steroids over time. Rajan et al. hypothesize that there may be distinct EoE phenotypes including "transient responders", which may help explain our observation ( 41 ) .
Although short-term effi cacy of swallowed FP has been previously demonstrated ( 14, (22) (23) (24) (25) (26) (27) (28) , signifi cant uncertainty regarding long-term safety and effi cacy remained concerning this off -label use of an otherwise very well established and safe medication. Two main concerns of long-term treatment with swallowed FP oft en raised are recurrent candida infections and alteration of the HPA axis with suppressed growth ( 47 ) . Our safety data showed a very low rate of local esophageal candida infections (three patients) that resolved with treatment without recurrence and without the need to discontinue swallowed FP. No impact on growth was noted in our patients. To better address questions about eff ects on the HPA axis, measurement of serum morning cortisol was started aft er completion of the study period. Cortisol levels were within the normal range for their age. None of the children showed clinical signs of adrenal insuffi ciency or delayed growth, and endocrine work-up was negative. In a recent publication by Butz et al. ( 28 ) , saliva cortisol levels did not show signifi cant alteration in patients treated with high-dose swallowed FP. Swallowed FP in the doses used in this study can be considered of low risk for long-term treatment of EoE in children, although further studies evaluating the eff ect of swallowed FP on the HPA axis, such as with an ACTH stimulation test, are warranted.
Other limitations to our study are its open-label, non-randomized design and the lack of a control group. However, a recently published randomized, double-blind placebo-controlled trial evaluating treatment with high-dose swallowed FP did not detect a signifi cant placebo eff ect, validating our approach ( 28 ) . In addition, a concern with the lack of randomization is selection bias that may limit the strength of our conclusions. However, given clinical evidence from randomized trials in adults (48) (49) (50) (51) (52) and children ( 22, 23, (25) (26) (27) (28) , equipoise among experts in the fi eld regarding the eff ectiveness of swallowed FP for EoE in children may have been eroded to the point that a randomized trial could be ethically problematic, especially in minors ( 53 ) . Furthermore, randomization of therapies were conducted at various points, including in the distant past before fl uticasone was off ered, and the diet had been already liberalized by then. Dietary therapy is known to be extremely diffi cult to maintain and adhere to, especially as patients get older and become more independent. Inconsistent adherence to diet was found to be a problem in some of our patients. All diets were fully liberalized at the start of swallowed fl uticasone.
Enrollment into our study started in 2006, before understanding the role PPIs have in EoE and before recommendations on PPI use in the consensus recommendations were available. Th ree of our patients continued PPI aft er start of swallowed FP, whereas all other patients discontinued PPI at enrollment into the study. Exclusion of those three patients did not change the primary and secondary outcomes. Th e patients remained in the group for the intention-to-treat analysis. A recent publication by Rajan et al. ( 41 ) also did not fi nd infl uence of PPI on eosinophilia or tissue remodeling.
As histological defi nition of remission is not yet established, we assessed diff erent peak eosinophil counts (<15, <10, and <5 eosinophils/HPF) for histologic remission as one of our secondary end points to validate established practice ( 18, 25, (42) (43) (44) (45) . Applying stringent criteria for defi nition of remission, the majority of patients reached and maintained peak eosinophil counts of <5 eosinophils/ HPF aft er initiation of treatment to the longest follow-up period. At all follow-up time points, 75% of patients in remission had a peak of <5 eosinophils/HPF, suggesting that true resolution of disease with swallowed FP might be associated with close to absent eosinophils in tissue biopsies and indicating that the doses we used, although generally not very high, were very eff ective.
We have demonstrated the eff ect of swallowed FP on fi brosis of the lamina propria in a previous study ( 13 ) . In this study, we were again able to demonstrate long-term complete resolution of lamina propria fi brosis in >50% of treated patients, starting as early as <4 months ( Table 3a ) . As discussed above, lamina propria adequate for evaluation was present in 75% of biopsies. Th ese results are not typically seen in adult patients with EoE ( 45 ) . It is possible that esophageal fi brosis in adult patients, as it has oft en developed over a longer period of time and undergone multiple disease remission and relapse cycles, is less responsive to treatment than in pediatric patients.
A recently published study investigating the long-term control of esophageal remodeling in patients with EoE supports the observation that, although esophageal remodeling is present in children and is associated with infl ammation, a substantial and sustainable response to swallowed topical steroids can be found. Th e authors described the main eff ect of swallowed topical steroids on fi brosis being exerted primarily via control of infl ammation, as lower fi brosis scores correlated with decreased number of esophageal eosinophils, rather than with treatment duration of swallowed topical steroids ( 41 ) . Th is fi nding supports our observation that a decrease in peak esophageal eosinophil levels is signifi cantly correlated with LP fi brosis reversal, with the underlying mechanism likely being infl ammation control.
Interestingly, relapse was more pronounced and frequent in the distal portion of the esophagus. All patients with relapse in the distal esophagus had decreased amounts of swallowed FP intake, either our patients into diet vs. swallowed FP, rather than giving them the choice, would have led to low adherence in several patients, making comparisons of therapy diffi cult. As detailed above, even though we allowed the families the choice of therapy, our analysis showed similar population characteristics among those that chose swallowed FP vs. diet as their fi rst treatment modality. Th erefore, we believe that our trial off ers the fi rst and best available evidence in support of long-term chronic use of swallowed FP to treat EoE in children and will allow for the fi rst time comfort in prescribing swallowed FP as a long-term therapeutic option for children with EoE, given its long-term effi cacy and safety profi le. Further investigation using larger multi-center trials is warranted to confi rm optimal long-term dosing regimens while providing maintenance of disease remission and minimizing potential side eff ects in children with EoE.
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Study Highlights
WHAT IS CURRENT KNOWLEDGE ✓ Swallowed steroids have been shown to be safe and effective as a short-term therapy in children with eosinophilic esophagitis (EoE).
✓ However, their effi cacy for chronic use has not been established.
WHAT IS NEW HERE
✓ Swallowed steroids are safe and effective when used as a long-term maintenance therapy in children with EoE.
✓ Treatment positively affects histological, endoscopic, and clinical features of EoE.
